Unlike everyday supplements stocked in every health store, CJC-1295 moves through a specialist research supply market that Heers residents navigate through international suppliers. The benefit of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than any physical store could provide. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram showing ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Heers researchers need to know about sourcing, verifying, and handling CJC-1295 for scientific research use.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Heers researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The most reliable path to quality CJC-1295 is community research first — peptide forums track vendor quality over time that are more accurate than commercial vendor claims. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone does not confirm what the compound actually is. Signs of a credible vendor beyond COA quality: documented vendor history spanning multiple years, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. The powdered lyophilised form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Heers
COA-verified · International tracking · Research grade
All use of CJC-1295 in Heers or anywhere must be research use only — this compound is not approved for human therapeutic use, and all handling should adhere to research compound handling standards. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — equivalent to 25mcg per unit on an insulin syringe. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no discount compensates for this missing data. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not approved for human use and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
